Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Stock · NYSE · Health Care
$18.03as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$16.6
Industry
Biotechnology: Pharmaceutical Preparations
Fundamentals
- Market cap
- $53.18B
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- —
- Avg. volume
- —
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) Competitors
Chosen by industry and closest market cap.
- TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)$18.04▲ 0.06%Market cap $53.18BP/E —
- ONCBeOne Medicines Ltd. American Depositary Shares$366.79▼ 1.53%Market cap $34.88BP/E 88.12$205.51$346
- ZTSZoetis Inc. Class A Common Stock$77.36▲ 3.12%Market cap $32.32BP/E 11.54$71$156.49
- ROIVRoivant Sciences Ltd. Common Shares$34.71▼ 7.64%Market cap $24.08BP/E —$11.85$37.97
- UTHRUnited Therapeutics Corporation Common Stock$515.57▼ 2.34%Market cap $21.92BP/E 17.03$302.19$609.35
- INSMInsmed Incorporated Common Stock$118.52▼ 2.36%Market cap $21.34BP/E —$90.39$212.75
- VTRSViatris Inc. Common Stock$16.34▼ 3.26%Market cap $20.53BP/E —$9.43$18.39
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TAK Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | $53.18B | — | $18.04 | ▲ 0.06% | |
| ONC BeOne Medicines Ltd. American Depositary Shares | $34.88B | 88.12 | $366.79 | ▼ 1.53% | $205.51$346 |
| ZTS Zoetis Inc. Class A Common Stock | $32.32B | 11.54 | $77.36 | ▲ 3.12% | $71$156.49 |
| ROIV Roivant Sciences Ltd. Common Shares | $24.08B | — | $34.71 | ▼ 7.64% | $11.85$37.97 |
| UTHR United Therapeutics Corporation Common Stock | $21.92B | 17.03 | $515.57 | ▼ 2.34% | $302.19$609.35 |
| INSM Insmed Incorporated Common Stock | $21.34B | — | $118.52 | ▼ 2.36% | $90.39$212.75 |
| VTRS Viatris Inc. Common Stock | $20.53B | — | $16.34 | ▼ 3.26% | $9.43$18.39 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Silence Therapeutics: Making Some Recent NoiseSeekingAlpha · 8/19/2026
- Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder DrugBenzinga · 8/13/2026
- Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’Benzinga · 8/13/2026
- Department Of Veterans Affairs Awards Takeda $5.6B Contract for Drugs And Biologicals Through 2031Benzinga · 8/10/2026
- Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term ConcernSeekingAlpha · 8/7/2026
- Takeda nets first-in-class advantage on narcolepsy drug’s FDA go-aheadYahoo · 8/6/2026
- Takeda approval ushers in new wave of sleep drugsYahoo · 8/6/2026
- Takeda Achieves Major Milestone With Holistic Narcolepsy Drug ApprovalBenzinga · 8/6/2026
Insider Activity
Insider Actions →Acquired
0
Disposed
565.0K
- Elaine Mary Shannon · August 11, 2026 · Sale20.4K @ $17.55
- Awny Samaan Botros Farajallah · August 10, 2026 · Sale14.0K @ $17.1
- Ramy Riad Ahmed Ibrahim · August 10, 2026 · Sale7.3K @ $17.1
- Rhonda Janice Pacheco · August 10, 2026 · Sale16.9K @ $17.1
- Lauren Rusckowski Duprey · August 10, 2026 · Sale47.6K @ $17.1
- Andrew Stewart Plump · August 10, 2026 · Sale165.4K @ $17.1
- Agosti Marcello Pignagnoli · August 10, 2026 · Sale23.0K @ $17.1
- Teresa Marie Bitetti · August 10, 2026 · Sale50.0K @ $17.1
- Elaine Mary Shannon · August 10, 2026 · Sale4.0K @ $17.1
- Gabriele Ricci · August 10, 2026 · Sale25.1K @ $17.1
- Nicola Deidre Petal Greenway · August 10, 2026 · Sale6.8K @ $17.1
- Julie So-Young Kim · August 10, 2026 · Sale89.1K @ $17.1
- Giles Richard Platford · August 10, 2026 · Sale31.1K @ $17.1
- Natalie Anne Marie Furney · August 10, 2026 · Sale30.9K @ $17.1
- Nicola Deidre Petal Greenway · August 10, 2026 · Sale33.6K @ $17.51
Institutional Ownership
March 31, 2026
- Total shares held
- 99.47M
- Total value held
- $1.78B
- Institutional holders
- 357
Top holders this quarter
- Unknown19.10M
- Unknown7.12M
- Unknown6.47M
- Unknown6.42M
- Unknown5.62M
- Unknown4.43M
- Unknown3.18M
- Unknown3.12M
- Unknown2.99M
- Unknown2.74M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedSynthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
August 29, 2026
Takeda's ORZEYFUL Approved in Japan for Narcolepsy Type 1. Takeda has received Japanese regulatory approval for ORZEYFUL, a treatment for narcolepsy type 1, following Phase 3 studies that showed significant improvements across the symptoms that were evaluated. The approval adds a new product to Takeda's portfolio in its domestic market. Shares have been holding above a well-tested support level near $18.12, with the recent price action suggesting buyers have stepped in at that area. Separately, the stock offers a dividend yield of 4.41%, which provides income alongside the company's commercial developments.